Dark Genome Therapeutics Market Size to Reach USD 11,945.7 Million in 2032

The Dark Genome Therapeutics market, valued at USD 2,155.7 million in 2024, is expected to register robust revenue CAGR of 23.8%.

Request free copy of this report: https://navistratanalytics.com/request-free-sample/1361

July 01, 2025 - Integration of AI and machine learning in genomics is a key driver driving dark genome therapeutics market revenue growth. AI systems developed for phenotypic and genomic analysis have proven useful in diagnosing uncommon diseases. The arrival of next-generation sequencing (NGS) about ten years ago transformed diagnostic techniques. Short-read sequencing (SRS) technologies, such as exome and genome sequencing, are becoming common diagnostic procedures for uncommon diseases. NGS is effective for diagnosing rare disorders, with diagnostic yields ranging from 25 to 50 percent.

On September 2024, Lucid Genomics, a pioneering Berlin-based startup spun off from the Max Planck Institute for Molecular Genetics and Charité - Universitätsmedizin Berlin, has raised Euro 1.3 million in pre-seed funding led by Caesar Ventures, with additional support from BIF Partners, Another.Vc, and the MPF Accelerator Programme. This investment will help Lucid Genomics expand its cutting-edge AI-Digital HealthTech platform, which is aimed to transform diagnostics and medication discovery by extracting important insights from genomic data and allowing for more precise development of targeted therapeutic treatments.

The encryption of genetic data for storage and computation presents several significant ethical and legal issues including informed consent and privacy. Research on the dark genome may reinforce genetic determinism and can fuel discrimination in areas like insurance, employment, and healthcare if dark genome elements. Also, studies exploring the dark genome often rely on large-scale genomic datasets. Patients may not fully understand the scope of what their data might reveal.

Want to Know What’s Fueling the Dark Genome Therapeutics Market Growth? Get Exclusive Report Insights Here: https://navistratanalytics.com/report_store/dark-genome-therapeutics-market/

Segments market overview and growth Insights

Based on the service type, the Dark Genome Therapeutics market is segmented into the Dark Genome Therapeutics market is segmented into Antisense Oligonucleotides (ASOs), small molecules, oligonucleotide vaccines, and monoclonal antibodies. The Oligonucleotide vaccines segment held the highest growth rate in 2024. Oligonucleotide vaccines can withstand the rapidly changing genomic sequences of RNA viruses by generating a long-lasting immune response through conserved portions of their genomes. Furthermore, oligonucleotide vaccines will not contribute to antibody-dependent increased infection since the coronavirus nucleic acid is contained within the viral particle.

Regional market overview and growth insights

North America held the largest market share in the Dark Genome Therapeutics market in 2024, due to advancements in genomics and Next-Generation Sequencing (NGS) and increased funding from governments and venture capitalists. On September 2023, ROME Therapeutics, a biotechnology company that uses the power of the dark genome to produce breakthrough therapies for critical diseases, has completed an oversubscribed USD 72 million Series B extension funding, bringing the entire Series B sum raised to USD 149 million.

Competitive Landscape and Key Competitors

The Dark Genome Therapeutics market is characterized by a fragmented structure, with many competitors holding a significant share of the market. List of major players included in the Dark Genome Therapeutics market report are:

• ROME Therapeutics
• HERVolution Therapeutics 
• HAYA Therapeutics
• Nucleome Therapeutics
• Enhanc3D Genomics Ltd
• NextRNA Therapeutics
• Amaroq Therapeutics
• Lucid Genomics GmbH
• NonExomics, LLC
• UbiVac

Buy Your Exclusive Copy Now: https://navistratanalytics.com/purchase-report/1361

Major strategic developments by leading competitors

HAYA Therapeutics, SA: In May 2025, HAYA Therapeutics, SA, a biotechnology business that pioneers precision RNA-guided regulatory genome targeted medicines that reprogram disease-driving cell states for rare, common, chronic, and age-related disorders, has announced a Series A fundraising round of USD 65 million. The funding will help HAYA speed the clinical development of its primary long non-coding RNA (lncRNA) candidate HTX-001 in heart failure, as well as the continuous expansion of its RNA-guided regulatory genome pipeline development engine.

HERVolution Therapeutics ApS: In December 2024, HERVolution Therapeutics ApS, a dark genome-focused biotechnology business creating immunotherapies to treat aging-related disorders, announced today a USD 11.7 million Series A funding round to push its main assets into clinical trials. Serum Institute of India (SII) led the investment round, which included participation from the European Innovation Council (EIC) Fund and other investors.

Unlock the Key to Transforming Your Business Strategy with Our Dark Genome Therapeutics Market Insights –

• Download the report summary: https://navistratanalytics.com/request-free-sample/ 1361
• Request customization: https://navistratanalytics.com/request-customization/1361

Navistrat Analytics has segmented dark genome therapeutics market based on therapeutic modality, target type, development stage, and application:

• Therapeutic Modality Outlook (Revenue, USD Million; 2022-2032)
  • Antisense Oligonucleotides (ASOs)
  • Small Molecules
  • Oligonucleotide Vaccines
  • Dark Genome Therapeutics
• Target Type Outlook (Revenue, USD Million; 2022-2032)
  • Long non-coding RNAs (lncRNAs)
  • LINE-1 Reverse Transcriptase (LINE-1 RT)
  • Human Endogenous Retroviruses (HERVs)
• Development Stage Outlook (Revenue, USD Million; 2022-2032)
  • Preclinical
  • Clinical
  • Post Clinical
• Application Outlook (Revenue, USD Million; 2022-2032)
  • Cancer
  • Autoimmune Diseases
  • Fibrotic Diseases
  • Neurodegenerative Disorders
  • Others
• Regional Outlook (Revenue, USD Million; 2022-2032)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Benelux
    • Nordic Countries
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Oceania
    • ASEAN Countries
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Turkey
    • Rest of MEA

Get a preview of the complete research study: https://navistratanalytics.com/report_store/dark-genome-therapeutics-market/

About Us:

At Navistrat Analytics, we provide high-quality, comprehensive syndicated and customized market research reports that deliver actionable insights and empower businesses through data-driven strategies. Choose Navistrat Analytics as your strategic growth partner for reliable market intelligence, and let us help you navigate the complexities of the market with clarity, precision, and confidence. 

Contact Us:

Navistrat Analytics

Visit Us: www.navistratanalytics.com                        

Email Us: Sales@navistratanalytics.com      

Asia-Pacific: +91-9073010653

Follow Us LinkedIn: https://www.linkedin.com/company/navistrat-analytics/